• Subscribe
    e

    Xconomy’s Digital Events →

    ▾
  • Xconomy National

  • Our
    Regions
    • National ›
      • Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4
        Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4
      View More in National ›
    • Europe ›
      • FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
        FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
      View More in Europe ›
    • Boston ›
      • Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects
        Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects
      View More in Boston ›
    • Boulder/Denver ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Boulder/Denver ›
    • Detroit/Ann Arbor ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Detroit/Ann Arbor ›
    • Indiana ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Indiana ›
    • New York ›
      • “Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
        “Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
      View More in New York ›
    • Philadelphia ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Philadelphia ›
    • Raleigh-Durham ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Raleigh-Durham ›
    • San Diego ›
      • Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
        Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
      View More in San Diego ›
    • San Francisco ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in San Francisco ›
    • Seattle ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Seattle ›
    • Texas ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Texas ›
    • Wisconsin ›
      • BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
        BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting
      View More in Wisconsin ›
  • Topic
    Channels
    • Life Sciences›
        View More in Life Sciences ›
      • Healthtech›
          View More in Healthtech ›
        • Robotics and A.I.›
            View More in Robotics and A.I. ›
          • Startups›
              View More in Startups ›
          • Our
            Events
            • All Xconomy Events ›
          • Xconomy
            Insight
          • Topic Channels
          • Healthtech
          • Life Sciences
          • Robotics and A.I.
          • Startups
          • Life Sciences

            • Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4

            • Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

            • Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies

            • Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

            • SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D

            • Life Sciences Home
          • Healthtech

            • Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

            • Healthcare AI Tech is Here, Now We Must Learn to Manage the Data

            • AI Can Unlock Health Data’s Potential, But Access Is Still Difficult

            • Nuance & Microsoft Team Up on Conversational AI for Doctors’ Offices

            • Five Years After Y Combinator First Admits Biotechs, They’re Dug In

            • Healthtech Home
          • Robotics and A.I.

            • Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More

            • Two Days, Six IPOs, and $1B Raised for Biotech Research & More

            • Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

            • Akili Interactive’s Video Game for ADHD Gets the FDA All Clear

            • Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System

            • Robotics and A.I. Home
          • Startups

            • Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

            • Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs

            • Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

            • Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More

            • Combined Therapeutics Inc Wins $250,000 MilliporeSigma Advance Biotech Grant

            • Startups Home

          Underwriters and Partners

          Xconomy on Demand

          We offer a number of ways to subscribe for free!

          Subscribe Now
          Informa Connect Logo Informa Connect Logo
          • Home
          • Privacy Policy
          • Security Disclosures
          • About
          • Contact Us
          • Archives
          • Advertise
          • Subscribe for Free

          © 2007-2022, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.